{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:22Z","timestamp":1787009002736,"version":"build-2736575974"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T00:00:00Z","timestamp":1505174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CS\/08\/08"],"award-info":[{"award-number":["CS\/08\/08"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["99999.008426\/2014-07"],"award-info":[{"award-number":["99999.008426\/2014-07"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,13]]},"DOI":"10.1093\/infdis\/jix479","type":"journal-article","created":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T15:06:33Z","timestamp":1505055993000},"page":"1118-1127","source":"Crossref","is-referenced-by-count":58,"title":["Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus"],"prefix":"10.1093","volume":"217","author":[{"given":"Clara E","family":"Negri","sequence":"first","affiliation":[{"name":"Laborat\u00f3rio Especial de Micologia, Disciplina de Infectologia, Escola Paulista de Medicina, Universidade Federal de S\u00e3o Paulo, Brazil"},{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Johnson","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"McEntee","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Box","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Whalley","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Davis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Ramos-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Livermore","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruwanthi","family":"Kolamunnage-Dona","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaldo L","family":"Colombo","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio Especial de Micologia, Disciplina de Infectologia, Escola Paulista de Medicina, Universidade Federal de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W","family":"Hope","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,9,12]]},"reference":[{"key":"key\n\t\t\t\t20180626074937_CIT0001","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1016\/j.ijid.2011.08.005","article-title":"Prognosis of acute invasive fungal rhinosinusitis related to underlying disease","volume":"15","author":"Valera","year":"2011","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20180626074937_CIT0002","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/myc.12314","article-title":"Epidemiology of chronic fungal rhinosinusitis in rural India","volume":"58","author":"Chakrabarti","year":"2015","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t20180626074937_CIT0003","first-page":"374","article-title":"Fungal rhino sinusitisin in Tehran, Iran","volume":"44","author":"Nazeri","year":"2015","journal-title":"Iran J Public Health"},{"key":"key\n\t\t\t\t20180626074937_CIT0004","doi-asserted-by":"crossref","first-page":"684835","DOI":"10.1155\/2012\/684835","article-title":"Fungal rhinosinusitis: a retrospective microbiologic and pathologic review of 400 patients at a single university medical center","volume":"2012","author":"Montone","year":"2012","journal-title":"Int J Otolaryngol"},{"key":"key\n\t\t\t\t20180626074937_CIT0005","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/jac\/dkv198","article-title":"Invasive mould sinusitis in patients with haematological malignancies: a 10 year single-centre study","volume":"70","author":"Davoudi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180626074937_CIT0006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2500\/ajra.2015.29.4115","article-title":"Prognostic factors for survival in patients with acute invasive fungal rhinosinusitis","volume":"29","author":"Cho","year":"2015","journal-title":"Am J Rhinol Allergy"},{"key":"key\n\t\t\t\t20180626074937_CIT0007","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/alr.21714","article-title":"An evaluation of invasive fungal sinusitis outcomes with subsite analysis and use of frozen section analysis","volume":"6","author":"Foshee","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"key\n\t\t\t\t20180626074937_CIT0008","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/INF.0000000000001015","article-title":"Prognostic factors in the outcome of invasive fungal sinusitis in a pediatric population","volume":"35","author":"Green","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20180626074937_CIT0009","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/lary.23912","article-title":"Survival outcomes in acute invasive fungal sinusitis: a systematic review and quantitative synthesis of published evidence","volume":"123","author":"Turner","year":"2013","journal-title":"Laryngoscope"},{"key":"key\n\t\t\t\t20180626074937_CIT0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180626074937_CIT0011","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.funbio.2012.08.006","article-title":"Molecular phylogeny and phenotypic variability of clinical and environmental strains of Aspergillus flavus","volume":"116","author":"Gon\u00e7alves","year":"2012","journal-title":"Fungal Biol"},{"key":"key\n\t\t\t\t20180626074937_CIT0012","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1128\/AAC.00637-15","article-title":"A novel Y319H substitution in CYP51C associated with azole resistance in Aspergillus flavus","volume":"59","author":"Paul","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180626074937_CIT0013","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3389\/fmicb.2016.01164","article-title":"Direct molecular diagnosis of aspergillosis and CYP51A profiling from respiratory samples of french patients","volume":"7","author":"Zhao","year":"2016","journal-title":"Front Microbiol"},{"key":"key\n\t\t\t\t20180626074937_CIT0014","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3109\/13693786.2012.684154","article-title":"Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection","volume":"50","author":"Hadrich","year":"2012","journal-title":"Med Mycol"},{"key":"key\n\t\t\t\t20180626074937_CIT0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jac\/42.4.497","article-title":"In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis","volume":"42","author":"Lass-Fl\u00f6rl","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180626074937_CIT0016","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/AAC.00383-13","article-title":"Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study)","volume":"57","author":"Alastruey-Izquierdo","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180626074937_CIT0017","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/jac\/dkx065","article-title":"Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans","volume":"72","author":"Wiederhold","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180626074937_CIT0018","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20180626074937_CIT0019","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1128\/JCM.01582-14","article-title":"Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles","volume":"52","author":"Negri","year":"2014","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180626074937_CIT0020","author":"EUCAST"},{"key":"key\n\t\t\t\t20180626074937_CIT0021","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi","author":"CLSI","year":"2009"},{"key":"key\n\t\t\t\t20180626074937_CIT0022","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/infdis\/jis372","article-title":"Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints","volume":"206","author":"Jeans","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074937_CIT0023","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/AAC.01364-15","article-title":"Pharmacodynamics of isavuconazole in a dynamic in vitro model of invasive pulmonary aspergillosis","volume":"60","author":"Box","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180626074937_CIT0024","unstructured":"Law D , BirchM, OliverJet al Pharmacokinetics of the Novel Antifungal Agent F901318 in Mice, Rats and Cynomolgus monkey. Fifty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California. September 18-21, 2015 (Abstract F-757)."},{"key":"key\n\t\t\t\t20180626074937_CIT0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20180626074937_CIT0026","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/infdis\/jir023","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy","volume":"203","author":"Howard","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074937_CIT0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.01157-17","article-title":"Pharmacodynamics of the orotomides against Aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease","volume":"8","author":"Hope","year":"2017","journal-title":"MBio"},{"key":"key\n\t\t\t\t20180626074937_CIT0028","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180626074937_CIT0029","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20180626074937_CIT0030","doi-asserted-by":"crossref","article-title":"Activity of F901318 against azole-resistant and difficult-to-treat Aspergillus species","author":"Buil","DOI":"10.26226\/morressier.56d6be7bd462b80296c95863"},{"key":"key\n\t\t\t\t20180626074937_CIT0031","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.mycmed.2016.01.002","article-title":"In vitro activities of five antifungal agents against 199 clinical and environmental isolates of Aspergillus flavus, an opportunistic fungal pathogen","volume":"26","author":"Khodavaisy","year":"2016","journal-title":"J Mycol Med"},{"key":"key\n\t\t\t\t20180626074937_CIT0032","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180626074937_CIT0033","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/infdis\/jis372","article-title":"Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints","volume":"206","author":"Jeans","year":"2012","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/217\/7\/1118\/25090709\/jix479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T06:02:17Z","timestamp":1602914537000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/217\/7\/1118\/4139715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,12]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,9,12]]},"published-print":{"date-parts":[[2018,3,13]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix479","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4,1]]},"published":{"date-parts":[[2017,9,12]]}}}